Article
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.
Pediatric blood & cancer - 1 Oct 2010
Kolb E Anders, Gorlick Richard, Houghton Peter J, Morton Christopher L, Neale Geoffrey, Keir Stephen T, Carol Hernan, Lock Richard, Phelps Doris, Kang Min H, Reynolds C Patrick, Maris John M, Billups Catherine, Smith Malcolm A
Abstract excerpt
BACKGROUND: AZD6244 (ARRY-142886) is a potent small molecule inhibitor of MEK1/2 that is in phase 2 clinical development. PROCEDURES: AZD6244 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel (1 nM-10 microM). In vivo AZD6244 was tested at a dose of 100 mg/kg administered orally twice daily 5 days per week for 6 weeks. Subsequently, AZD6244 was evaluated against two juvenile...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.